WO2009072604A1 - 抗nr10抗体、およびその利用 - Google Patents

抗nr10抗体、およびその利用 Download PDF

Info

Publication number
WO2009072604A1
WO2009072604A1 PCT/JP2008/072152 JP2008072152W WO2009072604A1 WO 2009072604 A1 WO2009072604 A1 WO 2009072604A1 JP 2008072152 W JP2008072152 W JP 2008072152W WO 2009072604 A1 WO2009072604 A1 WO 2009072604A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
prevention
useful
treatment
inflammatory diseases
Prior art date
Application number
PCT/JP2008/072152
Other languages
English (en)
French (fr)
Inventor
Taichi Kuramochi
Keiko Kasutani
Souhei Ohyama
Hiroyuki Tsunoda
Tomoyuki Igawa
Tatsuhiko Tachibana
Hirotaka Shiraiwa
Original Assignee
Chugai Seiyaku Kabushiki Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN200880126539.4A priority Critical patent/CN101939424B/zh
Priority to US12/745,781 priority patent/US20110129459A1/en
Application filed by Chugai Seiyaku Kabushiki Kaisha filed Critical Chugai Seiyaku Kabushiki Kaisha
Priority to KR1020167016319A priority patent/KR20160074019A/ko
Priority to CA2708532A priority patent/CA2708532C/en
Priority to DK08857126.0T priority patent/DK2236604T3/en
Priority to KR1020167013226A priority patent/KR20160062207A/ko
Priority to EP08857126.0A priority patent/EP2236604B1/en
Priority to JP2009544736A priority patent/JP5682995B2/ja
Priority to EP16172648.4A priority patent/EP3095862B9/en
Priority to RU2010127292/10A priority patent/RU2531521C2/ru
Priority to ES08857126.0T priority patent/ES2585480T3/es
Priority to KR1020177031058A priority patent/KR101840994B1/ko
Priority to AU2008332271A priority patent/AU2008332271C1/en
Priority to BRPI0821110A priority patent/BRPI0821110B8/pt
Priority to MX2010006096A priority patent/MX337081B/es
Priority to PCT/JP2009/054941 priority patent/WO2010064456A1/ja
Publication of WO2009072604A1 publication Critical patent/WO2009072604A1/ja
Priority to TW098141125A priority patent/TWI432209B/zh
Priority to CA2710264A priority patent/CA2710264C/en
Priority to BRPI0906478A priority patent/BRPI0906478B8/pt
Priority to KR1020107014700A priority patent/KR101271323B1/ko
Priority to PCT/JP2009/070376 priority patent/WO2010064697A1/ja
Priority to MYPI2010002989A priority patent/MY154715A/en
Priority to PL09830463T priority patent/PL2354161T3/pl
Priority to SI200931302T priority patent/SI2354161T1/sl
Priority to JP2010507563A priority patent/JP5139517B2/ja
Priority to DK09830463.7T priority patent/DK2354161T3/en
Priority to EP09830463.7A priority patent/EP2354161B1/en
Priority to HUE09830463A priority patent/HUE025958T2/en
Priority to RU2010126078/10A priority patent/RU2487136C2/ru
Priority to MX2010007936A priority patent/MX2010007936A/es
Priority to PT98304637T priority patent/PT2354161E/pt
Priority to AU2009323249A priority patent/AU2009323249B2/en
Priority to ES09830463.7T priority patent/ES2552690T3/es
Priority to US12/809,138 priority patent/US8575317B2/en
Priority to EP15172595.9A priority patent/EP2949672A1/en
Priority to CN200980106176.2A priority patent/CN101952318B/zh
Priority to HK11105170.8A priority patent/HK1151048A1/xx
Priority to US14/047,316 priority patent/US9399680B2/en
Priority to US14/340,883 priority patent/US20150175704A1/en
Priority to HRP20151215TT priority patent/HRP20151215T1/hr
Priority to US16/560,143 priority patent/US20200002429A1/en
Priority to US17/975,865 priority patent/US20230183363A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Abstract

　本発明者らは、ＮＲ１０に対して有効な中和活性を有する抗ＮＲ１０抗体を取得することに成功した。本発明によって提供される抗ＮＲ１０抗体は、例えば、炎症性疾患の治療もしくは予防のための医薬品として有用である。
PCT/JP2008/072152 2007-12-05 2008-12-05 抗nr10抗体、およびその利用 WO2009072604A1 (ja)

Priority Applications (42)

Application Number Priority Date Filing Date Title
AU2008332271A AU2008332271C1 (en) 2007-12-05 2008-12-05 Anti-NR10 antibody and use thereof
JP2009544736A JP5682995B2 (ja) 2007-12-05 2008-12-05 抗ｎｒ１０抗体、およびその利用
KR1020167016319A KR20160074019A (ko) 2007-12-05 2008-12-05 항ｎｒ１０ 항체 및 그의 이용
CA2708532A CA2708532C (en) 2007-12-05 2008-12-05 Anti-il31ra antibody and use thereof
DK08857126.0T DK2236604T3 (en) 2007-12-05 2008-12-05 The anti-NR10 antibody and use thereof
KR1020167013226A KR20160062207A (ko) 2008-12-05 2008-12-05 항ｎｒ１０ 항체 및 그의 이용
EP08857126.0A EP2236604B1 (en) 2007-12-05 2008-12-05 Anti-nr10 antibody and use thereof
CN200880126539.4A CN101939424B (zh) 2007-12-05 2008-12-05 抗nr10抗体及其应用
EP16172648.4A EP3095862B9 (en) 2007-12-05 2008-12-05 Anti-nr10 antibody and use thereof
ES08857126.0T ES2585480T3 (es) 2007-12-05 2008-12-05 Anticuerpo anti-NR10 y uso del mismo
RU2010127292/10A RU2531521C2 (ru) 2007-12-05 2008-12-05 Антитело против nr10 и его применение
KR1020177031058A KR101840994B1 (ko) 2007-12-05 2008-12-05 항ｎｒ１０ 항체 및 그의 이용
US12/745,781 US20110129459A1 (en) 2007-12-05 2008-12-05 Anti-nr10 antibody and use thereof
BRPI0821110A BRPI0821110B8 (pt) 2007-12-05 2008-12-05 anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
MX2010006096A MX337081B (es) 2007-12-05 2008-12-05 Anticuerpo anti-nr10 y su uso.
PCT/JP2009/054941 WO2010064456A1 (ja) 2008-12-05 2009-03-13 抗nr10抗体、およびその利用
TW098141125A TWI432209B (zh) 2008-12-05 2009-12-02 Anti-NR10 antibody and its use
CN200980106176.2A CN101952318B (zh) 2007-12-05 2009-12-04 抗nr10抗体及其应用
PCT/JP2009/070376 WO2010064697A1 (ja) 2008-12-05 2009-12-04 抗nr10抗体、およびその利用
PT98304637T PT2354161E (pt) 2008-12-05 2009-12-04 Anticorpo anti-nr10, e a sua utilização
KR1020107014700A KR101271323B1 (ko) 2008-12-05 2009-12-04 항ｎｒ１０ 항체 및 그의 이용
CA2710264A CA2710264C (en) 2007-12-05 2009-12-04 Anti-nr10 antibody and use thereof
MYPI2010002989A MY154715A (en) 2008-12-05 2009-12-04 Anti-nr10 antibody and use thereof
PL09830463T PL2354161T3 (pl) 2008-12-05 2009-12-04 Przeciwciało anty -NR10 i jego zastosowanie
SI200931302T SI2354161T1 (sl) 2008-12-05 2009-12-04 Anti-NR10 protitelo in njegova uporaba
JP2010507563A JP5139517B2 (ja) 2008-12-05 2009-12-04 抗ｎｒ１０抗体、およびその利用
DK09830463.7T DK2354161T3 (en) 2008-12-05 2009-12-04 ANTI-NR10 ANTIBODY AND USE THEREOF.
EP09830463.7A EP2354161B1 (en) 2008-12-05 2009-12-04 Anti-nr10 antibody, and use thereof
HUE09830463A HUE025958T2 (en) 2007-12-05 2009-12-04 Anti-NR10 antibody and application
RU2010126078/10A RU2487136C2 (ru) 2008-12-05 2009-12-04 Антитело против nr10 и его применение
MX2010007936A MX2010007936A (es) 2007-12-05 2009-12-04 Anticuerpo anti-nr-10 y su uso.
BRPI0906478A BRPI0906478B8 (pt) 2008-12-05 2009-12-04 anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
AU2009323249A AU2009323249B2 (en) 2007-12-05 2009-12-04 Anti-NR10 antibody, and use thereof
ES09830463.7T ES2552690T3 (es) 2008-12-05 2009-12-04 Anticuerpo anti-NR10 y uso del mismo
US12/809,138 US8575317B2 (en) 2007-12-05 2009-12-04 Anti-NR10 antibody and use thereof
EP15172595.9A EP2949672A1 (en) 2008-12-05 2009-12-04 Anti-nr10 antibody, and use thereof
HK11105170.8A HK1151048A1 (en) 2008-12-05 2011-05-24 Anti-nr 10 antibody, and use thereof nr10
US14/047,316 US9399680B2 (en) 2007-12-05 2013-10-07 Nucleic acids encoding anti-NR10 antibodies
US14/340,883 US20150175704A1 (en) 2007-12-05 2014-07-25 Anti-nr10 antibody and use thereof
HRP20151215TT HRP20151215T1 (hr) 2007-12-05 2015-11-12 Anti-nr10 protutijela i njihova uporaba
US16/560,143 US20200002429A1 (en) 2007-12-05 2019-09-04 Anti-nr10 antibody and use thereof
US17/975,865 US20230183363A1 (en) 2007-12-05 2022-10-28 Anti-nr10 antibody and use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2007315143 2007-12-05
JP2007-315143 2007-12-05
JP2008247425 2008-09-26
JP2008-247425 2008-09-26

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/745,781 A-371-Of-International US20110129459A1 (en) 2007-12-05 2008-12-05 Anti-nr10 antibody and use thereof
US14/340,883 Continuation US20150175704A1 (en) 2007-12-05 2014-07-25 Anti-nr10 antibody and use thereof

Publications (1)

Publication Number Publication Date
WO2009072604A1 true WO2009072604A1 (ja) 2009-06-11

Family

ID=40717782

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/072152 WO2009072604A1 (ja) 2007-12-05 2008-12-05 抗nr10抗体、およびその利用

Country Status (17)

Country Link
US (6) US20110129459A1 (ja)
EP (2) EP3095862B9 (ja)
JP (1) JP5682995B2 (ja)
KR (3) KR101643005B1 (ja)
CN (2) CN101939424B (ja)
AU (2) AU2008332271C1 (ja)
BR (1) BRPI0821110B8 (ja)
CA (2) CA2708532C (ja)
DK (1) DK2236604T3 (ja)
ES (2) ES2585480T3 (ja)
HR (1) HRP20151215T1 (ja)
HU (1) HUE025958T2 (ja)
MX (2) MX337081B (ja)
MY (1) MY177564A (ja)
RU (1) RU2531521C2 (ja)
TW (2) TWI548418B (ja)
WO (1) WO2009072604A1 (ja)

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101952318A (zh) * 2007-12-05 2011-01-19 中外制药株式会社 抗nr10抗体及其应用
WO2011055550A1 (ja) 2009-11-05 2011-05-12 国立大学法人大阪大学 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
WO2011090088A1 (ja) 2010-01-20 2011-07-28 中外製薬株式会社 安定化抗体含有溶液製剤
EP2354161A1 (en) * 2008-12-05 2011-08-10 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody, and use thereof
WO2011143318A3 (en) * 2010-05-11 2012-01-05 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
JPWO2010064697A1 (ja) * 2008-12-05 2012-05-10 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
WO2012091124A1 (ja) 2010-12-28 2012-07-05 中外製薬株式会社 動物細胞の培養方法
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
WO2013031237A1 (en) 2011-09-01 2013-03-07 Chugai Seiyaku Kabushiki Kaisha Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
US8431127B2 (en) 2007-12-05 2013-04-30 Chugai Seiyaku Kabushiki Kaisha Method for treating pruritus comprising administering an NR10 antagonist
JPWO2011108714A1 (ja) * 2010-03-04 2013-06-27 中外製薬株式会社 抗体定常領域改変体
US8562991B2 (en) 2008-09-26 2013-10-22 Chugai Seiyaku Kabushiki Kaisha Antibody molecules that bind to IL-6 receptor
US9028821B2 (en) 2006-06-08 2015-05-12 Chugai Seiyaku Kabushiki Kaisha Method of treating an inflammatory disease comprising administering an NR 10 antibody antagonist
WO2015099165A1 (ja) 2013-12-27 2015-07-02 中外製薬株式会社 等電点の低い抗体の精製方法
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
US9868948B2 (en) 2008-04-11 2018-01-16 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
JP2019504060A (ja) * 2016-01-08 2019-02-14 オンコバイオロジクス，インコーポレイティド モノクローナル抗体のアイソフォームを分離するための方法
US10253091B2 (en) 2009-03-19 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
WO2019225568A1 (ja) 2018-05-21 2019-11-28 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
WO2019230725A1 (ja) 2018-05-28 2019-12-05 中外製薬株式会社 充填ノズル
US10544227B2 (en) 2015-04-14 2020-01-28 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
US10604561B2 (en) 2016-09-16 2020-03-31 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US10774148B2 (en) 2015-02-27 2020-09-15 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
JP6845973B1 (ja) * 2019-11-20 2021-03-24 中外製薬株式会社 抗体含有製剤
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US11124576B2 (en) 2013-09-27 2021-09-21 Chungai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
KR20210145295A (ko) 2015-04-14 2021-12-01 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
WO2022025030A1 (ja) 2020-07-28 2022-02-03 中外製薬株式会社 新規改変型抗体を含む、針シールドを備えた針付プレフィルドシリンジ製剤
WO2022049614A1 (ja) 2020-09-01 2022-03-10 中外製薬株式会社 Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物
EP4056993A1 (en) 2014-08-20 2022-09-14 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
WO2023058723A1 (ja) 2021-10-08 2023-04-13 中外製薬株式会社 プレフィルドシリンジ製剤の調製方法
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
WO2023120561A1 (ja) * 2021-12-22 2023-06-29 中外製薬株式会社 生物活性が低下した抗体バリアント
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US11891432B2 (en) 2018-03-15 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2641444T3 (es) 2012-05-09 2017-11-10 Eli Lilly And Company Procedimiento de preparación de cloruros de 4-[[(benzoil)amino]sulfonil]benzoílo y preparación de acilsulfamoilbenzamidas
CA2881966C (en) 2012-08-24 2020-10-06 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
CN113773388A (zh) 2014-11-21 2021-12-10 百时美施贵宝公司 抗cd73抗体及其用途
MX2017006323A (es) 2014-11-21 2017-08-21 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
CN105331703B (zh) * 2015-11-16 2018-08-17 中国农业科学院北京畜牧兽医研究所 一种鉴定或辅助鉴定猪100kg体重眼肌面积的方法及其专用试剂盒
CA3029003A1 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
CN113637073B (zh) * 2020-05-11 2024-04-12 上海赛比曼生物科技有限公司 Bcma抗体及其制备和应用
CA3229982A1 (en) * 2021-08-30 2023-03-09 Galderma Holding SA Treatments for atopic dermatitis

Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0058481A1 (en) 1981-02-16 1982-08-25 Zeneca Limited Continuous release pharmaceutical compositions
EP0125023A1 (en) 1983-04-08 1984-11-14 Genentech, Inc. Recombinant immunoglobulin preparations, methods for their preparation, DNA sequences, expression vectors and recombinant host cells therefor
EP0133988A2 (de) 1983-08-02 1985-03-13 Hoechst Aktiengesellschaft Regulatorische Peptide enthaltende pharmazeutische Präparate mit protrahierter Freisetzung und Verfahren zu deren Herstellung
EP0239400A2 (en) 1986-03-27 1987-09-30 Medical Research Council Recombinant antibodies and methods for their production
JPH0159878B2 (ja) 1982-05-21 1989-12-20 Yunibaashitei Obu Karifuorunia
EP0404097A2 (de) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Bispezifische und oligospezifische, mono- und oligovalente Rezeptoren, ihre Herstellung und Verwendung
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1995001438A1 (en) 1993-06-30 1995-01-12 Medical Research Council Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1998013388A1 (fr) 1996-09-26 1998-04-02 Chugai Seiyaku Kabushiki Kaisha Anticorps contre les peptides lies a la parathormone humaine
WO1998046777A1 (fr) 1997-04-11 1998-10-22 Centre National De La Recherche Scientifique (Cnrs) Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
WO2000075314A1 (fr) 1999-06-02 2000-12-14 Chugai Research Institute For Molecular Medicine, Inc. Proteine receptrice d'hemopoietine
WO2003104453A1 (ja) 2002-06-05 2003-12-18 中外製薬株式会社 抗体作製方法
WO2005054467A1 (ja) 2003-12-03 2005-06-16 Chugai Seiyaku Kabushiki Kaisha 哺乳類βアクチンプロモーターを利用した発現系
WO2006070286A2 (en) * 2004-12-28 2006-07-06 Innate Pharma S.A. Monoclonal antibodies against nkg2a

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59162441U (ja) 1983-04-14 1984-10-31 千代田紙業株式会社 吹込口を有する重包包装
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5670373A (en) * 1988-01-22 1997-09-23 Kishimoto; Tadamitsu Antibody to human interleukin-6 receptor
US5322678A (en) * 1988-02-17 1994-06-21 Neorx Corporation Alteration of pharmacokinetics of proteins by charge modification
WO1992019759A1 (en) * 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
JPH0767688B2 (ja) 1992-01-21 1995-07-26 近畿コンクリート工業株式会社 Ｐｃコンクリートパネル
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
BR9204244A (pt) 1992-10-26 1994-05-03 Cofap Ferro fundido cinzento
WO1994012215A1 (en) 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with l-selectin
IL107742A0 (en) 1993-11-24 1994-02-27 Yeda Res & Dev Chemically-modified binding proteins
DE4419399C1 (de) 1994-06-03 1995-03-09 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von heterologen bispezifischen Antikörpern
US5945311A (en) 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
US8017121B2 (en) * 1994-06-30 2011-09-13 Chugai Seiyaku Kabushika Kaisha Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
AU700819B2 (en) 1994-10-07 1999-01-14 Chugai Seiyaku Kabushiki Kaisha Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
CN101829325A (zh) * 1994-10-21 2010-09-15 岸本忠三 Il-6受体的抗体在制备药物组合物中的用途
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
FR2729855A1 (fr) 1995-01-26 1996-08-02 Oreal Utilisation d'un antagoniste de cgrp dans une composition cosmetique, pharmaceutique ou dermatologique et composition obtenue
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
CN1241944C (zh) 1995-09-11 2006-02-15 协和发酵工业株式会社 抗人白介素－5受体α链的抗体
EP0938499A1 (en) 1996-07-19 1999-09-01 Amgen Inc. Analogs of cationic proteins
US20070059302A1 (en) * 1997-04-07 2007-03-15 Genentech, Inc. Anti-vegf antibodies
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
RU2221809C2 (ru) * 1997-10-03 2004-01-20 Тугаи Сейяку Кабусики Кайся Способ получения природного гуманизированного антитела
DK1074268T3 (da) * 1998-03-17 2008-04-28 Chugai Pharmaceutical Co Ltd IL-6-receptorantagonistantistofholdige forebyggende eller terapeutiske midler mod inflammatoriske tarmsygdomme
CN1303431A (zh) 1998-04-03 2001-07-11 中外制药株式会社 抗人组织因子和人源化抗体以及人源化抗体的制作方法
CN101070344A (zh) 1998-04-30 2007-11-14 泰诺士公司 G－csf受体兴奋剂抗体及其筛选方法
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
FR2780062B1 (fr) 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa Anticorps monoclonaux diriges contre la proteine g3bp, et leurs utilisations
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
KR100483494B1 (ko) * 1998-12-01 2005-04-15 프로테인 디자인 랩스 인코포레이티드 감마 인터페론에 대한 인간화 항체
JP2002534959A (ja) 1998-12-08 2002-10-22 バイオベーション リミテッド 免疫原性タンパク質の改変方法
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6972125B2 (en) 1999-02-12 2005-12-06 Genetics Institute, Llc Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SE9903895D0 (sv) 1999-10-28 1999-10-28 Active Biotech Ab Novel compounds
AU6627201A (en) 2000-05-03 2001-11-12 Mbt Munich Biotechnology Gmbh Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
US20030096339A1 (en) * 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
JP4889187B2 (ja) * 2000-10-27 2012-03-07 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
CA2440221C (en) 2001-03-07 2013-02-05 Merck Patent Gesellschaft Mit Beschraenkter Haftung Expression technology for proteins containing a hybrid isotype antibody moiety
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
PL366469A1 (en) 2001-04-05 2005-02-07 Immuno-Biological Laboratories Co, Ltd. Anti-osteopontin antibody and use thereof
WO2002083854A2 (en) 2001-04-13 2002-10-24 Biogen, Inc. Antibodies to vla-1
EP2208784B1 (en) * 2001-06-22 2013-01-02 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors containing anti-glypican 3 antibody
CA2473733C (en) * 2002-01-18 2014-09-09 Zymogenetics, Inc. Cytokine receptor zcytor17 multimers
JP4795641B2 (ja) 2002-01-18 2011-10-19 ザイモジェネティクス， インコーポレイテッド 新規サイトカインｚｃｙｔｏｒ１７リガンド
US20050130224A1 (en) 2002-05-31 2005-06-16 Celestar Lexico- Sciences, Inc. Interaction predicting device
WO2003105757A2 (en) 2002-06-12 2003-12-24 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
TW200407335A (en) * 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
US20040086979A1 (en) 2002-08-15 2004-05-06 Dongxiao Zhang Humanized rabbit antibodies
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
KR100499989B1 (ko) 2002-12-27 2005-07-07 네오바이오다임 주식회사 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 아사이알로 α1-산 당단백질에 대한 단일클론 항체, 이 항체를 포함하는 면역크로마토그래피 스트립 및 이 스트립를 이용한 아사이알로 α1-산 당단백질 측정방법
EP1608684A2 (en) 2003-02-07 2005-12-28 Protein Design Labs, Inc. Amphiregulin antibodies and their use to treat cancer and psoriasis
US20040223970A1 (en) * 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
JP2006521387A (ja) 2003-03-04 2006-09-21 アレクシオン ファーマシューティカルズ， インコーポレイテッド 寛容誘導抗原提示細胞による抗原提示の誘導によって自己免疫疾患を治療する方法
ATE475673T1 (de) 2003-03-24 2010-08-15 Zymogenetics Inc Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
WO2004113387A2 (en) 2003-06-24 2004-12-29 Merck Patent Gmbh Tumour necrosis factor receptor molecules with reduced immunogenicity
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
AU2003271186A1 (en) * 2003-10-14 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
EP1701979A2 (en) * 2003-12-03 2006-09-20 Xencor, Inc. Optimized antibodies that target the epidermal growth factor receptor
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
AP2006003689A0 (en) 2004-01-09 2006-08-31 Pfizer Antibodies to MAdCAM
AU2005227326B2 (en) * 2004-03-24 2009-12-03 Xencor, Inc. Immunoglobulin variants outside the Fc region
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
EP1773391A4 (en) 2004-06-25 2009-01-21 Medimmune Inc INCREASING THE PRODUCTION OF RECOMBINANT ANTIBODIES IN MAMMALIAN CELLS BY MUTAGENESIS ON THE SITE
BRPI0510674A (pt) 2004-07-15 2007-12-26 Xencor Inc variantes fc otimizadas
US20080233131A1 (en) 2004-09-14 2008-09-25 Richard John Stebbings Vaccine
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
WO2006047350A2 (en) 2004-10-21 2006-05-04 Xencor, Inc. IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
AU2005299716B2 (en) * 2004-10-22 2012-09-06 Amgen Inc. Methods for refolding of recombinant antibodies
US7632497B2 (en) * 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
JPWO2006067847A1 (ja) 2004-12-22 2008-06-12 中外製薬株式会社 フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
US20090087478A1 (en) 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
JP4986633B2 (ja) 2005-01-12 2012-07-25 協和発酵キリン株式会社 安定化されたヒトＩｇＧ２およびＩｇＧ３抗体
EP1858925A2 (en) * 2005-01-12 2007-11-28 Xencor, Inc. Antibodies and fc fusion proteins with altered immunogenicity
WO2006088855A1 (en) * 2005-02-14 2006-08-24 Zymogenetics, Inc. Methods of treating skin disorders using an il-31ra antagonist
ES2592271T3 (es) 2005-03-31 2016-11-29 Chugai Seiyaku Kabushiki Kaisha Métodos de producción de polipéptidos mediante la regulación de la asociación de los polipéptidos
EP1876236B9 (en) * 2005-04-08 2015-02-25 Chugai Seiyaku Kabushiki Kaisha Antibody substituting for function of blood coagulation factor viii
MY148086A (en) 2005-04-29 2013-02-28 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods using same
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
WO2007143231A2 (en) 2006-01-10 2007-12-13 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
US20070134234A1 (en) 2005-09-29 2007-06-14 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
CA2625773C (en) 2005-10-14 2015-05-12 Fukuoka University Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
DK2463305T3 (en) * 2006-01-12 2016-08-29 Alexion Pharma Inc Antibodies to OX-2 / CD200 and uses thereof
RS51723B2 (sr) * 2006-03-23 2018-03-30 Bioarctic Neuroscience Ab Poboljšana antitela selektivna za protofibrile i njihova primena
AU2007227963A1 (en) * 2006-03-23 2007-09-27 Kyowa Hakko Kirin Co., Ltd. Agonist antibody to human thrombopoietin receptor
WO2007114325A1 (ja) * 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 二重特異性抗体を精製するための抗体改変方法
EP4001409A1 (en) 2006-03-31 2022-05-25 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US9260516B2 (en) * 2006-04-07 2016-02-16 Osaka University Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor
CL2007001665A1 (es) 2006-06-08 2008-01-18 Chugai Pharmaceutical Co Ltd Anticuerpo o fragmento del mismo con actividad neutralizante de la proteina nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.
ES2415655T3 (es) * 2006-06-15 2013-07-26 The Board Of Trustees Of The University Of Arkansas Anticuerpos monoclonales que reconocen selectivamente Metanfetamina y compuestos similares a Metanfetamina
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
EP2069404B1 (en) * 2007-02-14 2011-01-05 Vaccinex, Inc. Humanized anti-cd100 antibodies
PL2426144T3 (pl) 2007-02-23 2019-05-31 Merck Sharp & Dohme Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
JPWO2008114733A1 (ja) * 2007-03-16 2010-07-01 協和発酵キリン株式会社 抗Ｃｌａｕｄｉｎ−４抗体
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
EP2155790A1 (en) 2007-05-31 2010-02-24 Genmab A/S Method for extending the half-life of exogenous or endogenous soluble molecules
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
MX342551B (es) 2007-09-26 2016-10-04 Chugai Pharmaceutical Co Ltd Region constante de anticuerpo modificada.
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
BRPI0817250A2 (pt) * 2007-09-26 2014-06-17 Chugai Pharmaceutical Co Ltd Anticorpo anti-receptor da il-6.
WO2009041062A1 (ja) * 2007-09-28 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 血漿中動態が改善されたグリピカン３抗体
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US20110129459A1 (en) 2007-12-05 2011-06-02 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody and use thereof
CN104162155A (zh) 2007-12-05 2014-11-26 中外制药株式会社 搔痒症治疗药
AU2009212273B2 (en) 2008-02-08 2014-07-31 Astrazeneca Ab Anti-IFNAR1 antibodies with reduced Fc ligand affinity
NZ602884A (en) 2008-04-11 2014-08-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9315577B2 (en) 2008-05-01 2016-04-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP5787446B2 (ja) 2009-03-19 2015-09-30 中外製薬株式会社 抗体定常領域改変体
JP5717624B2 (ja) * 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
EP2481752B1 (en) * 2009-09-24 2016-11-09 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
WO2011108714A1 (ja) * 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
JP5932670B2 (ja) 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体

Patent Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0058481A1 (en) 1981-02-16 1982-08-25 Zeneca Limited Continuous release pharmaceutical compositions
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
JPH0159878B2 (ja) 1982-05-21 1989-12-20 Yunibaashitei Obu Karifuorunia
EP0125023A1 (en) 1983-04-08 1984-11-14 Genentech, Inc. Recombinant immunoglobulin preparations, methods for their preparation, DNA sequences, expression vectors and recombinant host cells therefor
EP0133988A2 (de) 1983-08-02 1985-03-13 Hoechst Aktiengesellschaft Regulatorische Peptide enthaltende pharmazeutische Präparate mit protrahierter Freisetzung und Verfahren zu deren Herstellung
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
EP0239400A2 (en) 1986-03-27 1987-09-30 Medical Research Council Recombinant antibodies and methods for their production
EP0404097A2 (de) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Bispezifische und oligospezifische, mono- und oligovalente Rezeptoren, ihre Herstellung und Verwendung
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992020791A1 (en) 1990-07-10 1992-11-26 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011161A1 (en) 1991-11-25 1993-06-10 Enzon, Inc. Multivalent antigen-binding proteins
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993019172A1 (en) 1992-03-24 1993-09-30 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1994002602A1 (en) 1992-07-24 1994-02-03 Cell Genesys, Inc. Generation of xenogeneic antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1995001438A1 (en) 1993-06-30 1995-01-12 Medical Research Council Sbp members with a chemical moiety covalently bound within the binding site; production and selection thereof
WO1995015388A1 (en) 1993-12-03 1995-06-08 Medical Research Council Recombinant binding proteins and peptides
WO1996002576A1 (fr) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Anticorps humain reconstitue contre l'interleukine-8 humaine
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1998013388A1 (fr) 1996-09-26 1998-04-02 Chugai Seiyaku Kabushiki Kaisha Anticorps contre les peptides lies a la parathormone humaine
WO1998046777A1 (fr) 1997-04-11 1998-10-22 Centre National De La Recherche Scientifique (Cnrs) Preparation de recepteurs membranaires a partir de baculovirus extracellulaires
WO2000075314A1 (fr) 1999-06-02 2000-12-14 Chugai Research Institute For Molecular Medicine, Inc. Proteine receptrice d'hemopoietine
WO2003104453A1 (ja) 2002-06-05 2003-12-18 中外製薬株式会社 抗体作製方法
WO2005054467A1 (ja) 2003-12-03 2005-06-16 Chugai Seiyaku Kabushiki Kaisha 哺乳類βアクチンプロモーターを利用した発現系
WO2006070286A2 (en) * 2004-12-28 2006-07-06 Innate Pharma S.A. Monoclonal antibodies against nkg2a

Non-Patent Citations (72)

* Cited by examiner, † Cited by third party
Title
"Heterogeneity of Monoclonal Antibodies", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 97, no. 7, pages 2426 - 2447
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10
ANAL BIOCHEM., vol. 360, no. 1, 1 January 2007 (2007-01-01), pages 75 - 83
ANN HEMATOL., vol. 76, no. 6, June 1998 (1998-06-01), pages 231 - 48
BETTER ET AL., SCIENCE, vol. 240, 1988, pages 1041 - 1043
BETTER, M.; HORWITZ, A. H., METHODS ENZYMOL., vol. 178, 1989, pages 476 - 496
BETTER, M.; HORWITZ, A. H., METHODS IN ENZYMOLOGY, vol. 178, 1989, pages 476 - 496
BIOCHEM. BIOPHYS. RES. COMMUN., vol. 228, 1996, pages 838 - 45
BIRD, R. E. ET AL., TIBTECH, vol. 9, 1991, pages 132 - 137
BIRD, R. E.; WALKER, B. W., TRENDS BIOTECHNOL., vol. 9, 1991, pages 132 - 137
CANCER RES., vol. 53, no. 4, 15 February 1993 (1993-02-15), pages 851 - 6
CHIRINO AJ. ET AL.: "Minimizing the immunogenicity of protein therapeutics", DRUG DISCOV. TODAY, vol. 9, no. 2, 2004, pages 82 - 90, XP002395255 *
CO, M. S. ET AL., J. IMMUNOL., vol. 152, 1994, pages 2968 - 2976
CO, M.S. ET AL., J. IMMUNOL., vol. 152, 1994, pages 2968 - 2976
DALBADIE-MCFARLAND, G. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 79, 1982, pages 6409 - 13
DILLON SR. ET AL.: "Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice", NAT. IMMUNOL., vol. 5, no. 7, 2004, pages 752 - 760, XP002407998 *
DIVEU C. ET AL.: "GPL, a novel cytokine receptor related to GP130 and leukemia inhibitory factor receptor", J. BIOL. CHEM., vol. 278, no. 50, 2003, pages 49850 - 49859, XP002475880 *
EUR J IMMUNOL., vol. 29, no. 8, August 1999 (1999-08-01), pages 2613 - 24
EWERT S. ET AL.: "Stability improvement of antibodies for extracellular and intracellular applications: CDR grafting to stable frameworks and structure-based framework engineering", METHODS, vol. 34, no. 2, 2004, pages 184 - 199, XP008133067 *
FASEB J., vol. 6, 1992, pages 2422 - 2427
HANES J. ET AL.: "Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display", NAT. BIOTECHNOL., vol. 18, no. 12, 2000, pages 1287 - 1292, XP001121946 *
HASHIMOTO-GOTOH, T; MIZUNO, T; OGASAHARA, Y; NAKAGAWA, M.: "An oligodeoxyribonucleotide-directed dual amber method for site-directed mutagenesis", GENE, vol. 152, 1995, pages 271 - 275
HOLLIGER P ET AL., PROC. NATL ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
HOPP, T. P. ET AL., BIOTECHNOLOGY, vol. 6, 1988, pages 1204 - 1210
HUDSON ET AL., J IMMUNOL. METHODS, vol. 231, 1999, pages 177 - 189
HUSTON, J. S. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 5879 - 5883
INT. IMMUNOL., vol. 18, no. 12, December 2006 (2006-12-01), pages 1759 - 69
J ALLERGY CLIN IMMUNOL., vol. 117, no. 2, February 2006 (2006-02-01), pages 418 - 25
J BIOL CHEM, vol. 277, 2002, pages 16831 - 6
J BIOL CHEM, vol. 278, 2003, pages 49850 - 9
J BIOL CHEM., vol. 283, no. 23, 6 June 2008 (2008-06-06), pages 16206 - 15
J PHARM SCI., vol. 97, no. 4, April 2008 (2008-04-01), pages 1414 - 26
J. BIOL. CHEM., vol. 282, no. 3, 19 January 2007 (2007-01-19), pages 1709 - 17
J. EXP. MED., vol. 180, no. 6, 1994, pages 2377 - 2381
J. IMMUNOL., vol. 169, no. 9, 1 November 2002 (2002-11-01), pages 5171 - 80
J. IMMUNOL., vol. 176, no. 1, 1 January 2006 (2006-01-01), pages 346 - 56
KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5G73 - 7
KOHLER, G.; MILSTEIN, C., METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46
KOHLER. G.; MILSTEIN, C., METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46
KRAMER W; FRITZ HJ: "Oligonucleotide-directed construction of mutations via gapped duplex DNA Methods", ENZYMOL., vol. 154, 1987, pages 350 - 367
KRAMER, W; DRUTSA, V; JANSEN, HW; KRAMER, B; PFLUGFELDER, M; FRITZ, HJ: "The gapped duplex DNA approach to oligonucleotide-directed mutation construction", NUCLEIC ACIDS RES., vol. 12, 1984, pages 9441 - 9456
KUNKEL, TA: "Rapid and efficient site-specific mutagenesis without phenotypic selection", PROC NATL ACAD SCI USA., vol. 82, 1985, pages 488 - 492
LAMOYI, E., METHODS ENZYMOL., vol. 121, 1986, pages 652 - 663
LAMOYI, E., METHODS IN ENZYMOLOGY, vol. 121, 1989, pages 652 - 663
LANGER ET AL., J. BIOMED. MATER. RES., vol. 15, 1981, pages 167 - 277
LANGER, CHEM. TECH., vol. 12, 1982, pages 98 - 105
LEI, S. P. ET AL., J. BACTERIAL., vol. 169, 1987, pages 4379
MARK, D. F. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 5662 - 6
METHODS, vol. 34, no. 4, December 2004 (2004-12-01), pages 468 - 75
MIZUSHIMA ET AL., NUCLEIC ACIDS RES., vol. 18, 1990, pages 5322
MULLIGAN ET AL., NATURE, vol. 277, 1979, pages 108
NAT BIOTECHNOL., vol. 25, no. 12, December 2007 (2007-12-01), pages 1369 - 72
NAT IMMUNOL, vol. 5, 2004, pages 752 - 60
NAT REV IMMUNOL., vol. 7, no. 9, September 2007 (2007-09-01), pages 715 - 25
NAT. BIOTECHNOL., vol. 25, no. 12, December 2007 (2007-12-01), pages 1369 - 72
NUCLEIC ACIDS. RES., vol. 18, no. 17, 1990, pages 5322
PACE ET AL., PROTEIN SCIENCE, vol. 4, 1995, pages 2411 - 2423
PLUCKTHUN, A.; SKERRA, A., METHODS ENZYMOL., vol. 178, 1989, pages 497 - 515
PLUECKTHUN, A.; SKERRA, A., METHODS IN ENZYMOLOGY, vol. 178, 1989, pages 476 - 496
PROC. NATL. ACAD. SCI. U.S.A., vol. 99, no. 26, 2002, pages 16899 - 16903
PROC. NATL. ACAD. SCI. USA., vol. 103, no. 49, 5 December 2006 (2006-12-05), pages 18709 - 14
PROTEIN ENGINEERING, vol. 9, no. 3, 1996, pages 299 - 305
ROUSSEAUX, J. ET AL., METHODS ENZYMOL., vol. 121, 1986, pages 663 - 669
ROUSSEAUX, J. ET AL., METHODS IN ENZYMOLOGY, vol. 121, 1989, pages 663 - 669
SATO, K. ET AL., CANCER RES., vol. 53, 1993, pages 851 - 856
See also references of EP2236604A4
SIDMAN ET AL., BIOPOLYMERS, vol. 22, 1983, pages 547 - 56
TAN PH. ET AL.: "Engineering the isoelectric point of a renal cell carcinoma targeting antibody greatly enhances scFv solubility", IMMUNOTECHNOLOGY, vol. 4, no. 2, 1998, pages 107 - 114, XP004153635 *
WANG, A. ET AL., SCIENCE, vol. 224, 1984, pages 1431 - 3
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546
ZOLLER, M. J.; SMITH, M., NUCLEIC ACIDS RES., vol. 10, 1982, pages 6487 - 500
ZOLLER, MJ; SMITH, M.: "Oligonucleotide-directed mutagenesis of DNA fragments cloned into M13 vectors", METHODS ENZYMOL., vol. 100, 1983, pages 468 - 500

Cited By (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168344B2 (en) 2005-03-31 2021-11-09 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US10011858B2 (en) 2005-03-31 2018-07-03 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US10934344B2 (en) 2006-03-31 2021-03-02 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
US9028821B2 (en) 2006-06-08 2015-05-12 Chugai Seiyaku Kabushiki Kaisha Method of treating an inflammatory disease comprising administering an NR 10 antibody antagonist
US9745378B2 (en) 2006-06-08 2017-08-29 Chugai Seiyaku Kabushiki Kaisha Antibodies that bind to cytokine receptor NR10
US11248053B2 (en) 2007-09-26 2022-02-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9828429B2 (en) 2007-09-26 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
US11332533B2 (en) 2007-09-26 2022-05-17 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
US9096651B2 (en) 2007-09-26 2015-08-04 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in CDR
EP3415529A1 (en) * 2007-09-26 2018-12-19 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
US9399680B2 (en) 2007-12-05 2016-07-26 Chugai Seiyaku Kabushiki Kaisha Nucleic acids encoding anti-NR10 antibodies
CN101952318A (zh) * 2007-12-05 2011-01-19 中外制药株式会社 抗nr10抗体及其应用
CN101952318B (zh) * 2007-12-05 2014-07-09 中外制药株式会社 抗nr10抗体及其应用
US8431127B2 (en) 2007-12-05 2013-04-30 Chugai Seiyaku Kabushiki Kaisha Method for treating pruritus comprising administering an NR10 antagonist
US10472623B2 (en) 2008-04-11 2019-11-12 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US11359194B2 (en) 2008-04-11 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding two or more antigen molecules repeatedly
US9868948B2 (en) 2008-04-11 2018-01-16 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US11371039B2 (en) 2008-04-11 2022-06-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US9890377B2 (en) 2008-04-11 2018-02-13 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
US8562991B2 (en) 2008-09-26 2013-10-22 Chugai Seiyaku Kabushiki Kaisha Antibody molecules that bind to IL-6 receptor
US10662245B2 (en) 2008-09-26 2020-05-26 Chugai Seiyaku Kabushiki Kaisha Methods of reducing IL-6 activity for disease treatment
EP2354161A4 (en) * 2008-12-05 2013-01-02 Chugai Pharmaceutical Co Ltd ANTI-NR10 ANTIBODIES AND CORRESPONDING USE
EP2949672A1 (en) * 2008-12-05 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody, and use thereof
JP5139517B2 (ja) * 2008-12-05 2013-02-06 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
JPWO2010064697A1 (ja) * 2008-12-05 2012-05-10 中外製薬株式会社 抗ｎｒ１０抗体、およびその利用
EP2354161A1 (en) * 2008-12-05 2011-08-10 Chugai Seiyaku Kabushiki Kaisha Anti-nr10 antibody, and use thereof
US10253091B2 (en) 2009-03-19 2019-04-09 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10066018B2 (en) 2009-03-19 2018-09-04 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
WO2011055550A1 (ja) 2009-11-05 2011-05-12 国立大学法人大阪大学 自己免疫疾患又はアレルギー治療剤とそのスクリーニング方法
EP3275898A1 (en) 2009-11-05 2018-01-31 Osaka University Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
US10022319B2 (en) 2010-01-20 2018-07-17 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing liquid formulations
EP3892292A2 (en) 2010-01-20 2021-10-13 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing liquid formulations
EP3378486A2 (en) 2010-01-20 2018-09-26 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing liquid formulations
WO2011090088A1 (ja) 2010-01-20 2011-07-28 中外製薬株式会社 安定化抗体含有溶液製剤
US11612562B2 (en) 2010-01-20 2023-03-28 Chugai Seiyaku Kabushiki Kaisha Solution preparation containing stabilized antibody
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
JP5889181B2 (ja) * 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
JPWO2011108714A1 (ja) * 2010-03-04 2013-06-27 中外製薬株式会社 抗体定常領域改変体
US8481688B2 (en) 2010-05-11 2013-07-09 Aveo Pharmaceuticals, Inc. Anti-FGFR2 antibodies
WO2011143318A3 (en) * 2010-05-11 2012-01-05 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
US11891434B2 (en) 2010-11-30 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
CN103282509A (zh) * 2010-12-28 2013-09-04 中外制药株式会社 动物细胞的培养方法
US20130295613A1 (en) * 2010-12-28 2013-11-07 Chugai Seiyaku Kabushiki Kaisha Animal cell culturing method
WO2012091124A1 (ja) 2010-12-28 2012-07-05 中外製薬株式会社 動物細胞の培養方法
JP6001456B2 (ja) * 2010-12-28 2016-10-05 中外製薬株式会社 動物細胞の培養方法
WO2013012022A1 (ja) 2011-07-19 2013-01-24 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
EP3235557A1 (en) 2011-09-01 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
WO2013031237A1 (en) 2011-09-01 2013-03-07 Chugai Seiyaku Kabushiki Kaisha Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
US11124576B2 (en) 2013-09-27 2021-09-21 Chungai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
WO2015099165A1 (ja) 2013-12-27 2015-07-02 中外製薬株式会社 等電点の低い抗体の精製方法
EP4056993A1 (en) 2014-08-20 2022-09-14 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
US10774148B2 (en) 2015-02-27 2020-09-15 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
KR20240033097A (ko) 2015-04-14 2024-03-12 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
KR20230043246A (ko) 2015-04-14 2023-03-30 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
KR20210145295A (ko) 2015-04-14 2021-12-01 추가이 세이야쿠 가부시키가이샤 Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물
US11773173B2 (en) 2015-04-14 2023-10-03 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
US10544227B2 (en) 2015-04-14 2020-01-28 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis comprising IL-31 antagonist as active ingredient
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
JP2019504060A (ja) * 2016-01-08 2019-02-14 オンコバイオロジクス，インコーポレイティド モノクローナル抗体のアイソフォームを分離するための方法
US11780908B2 (en) 2016-09-16 2023-10-10 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies, polypeptides containing variant FC regions, and methods of use
US10604561B2 (en) 2016-09-16 2020-03-31 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US10844113B2 (en) 2016-09-16 2020-11-24 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use
US11851486B2 (en) 2017-05-02 2023-12-26 National Center Of Neurology And Psychiatry Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
US11891432B2 (en) 2018-03-15 2024-02-06 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use
WO2019225568A1 (ja) 2018-05-21 2019-11-28 中外製薬株式会社 ガラス容器に封入された凍結乾燥製剤
WO2019230725A1 (ja) 2018-05-28 2019-12-05 中外製薬株式会社 充填ノズル
US11260125B2 (en) 2019-11-20 2022-03-01 Chugai Seiyaku Kabushiki Kaisha Anti-IL31RA antibody-containing formulations
KR20220098046A (ko) 2019-11-20 2022-07-08 추가이 세이야쿠 가부시키가이샤 항체 함유 제제
US11723976B2 (en) 2019-11-20 2023-08-15 Chugai Seiyaku Kabushiki Kaisha Methods of administering anti-IL31A antibody-containing formulations
JP2021169448A (ja) * 2019-11-20 2021-10-28 中外製薬株式会社 抗体含有製剤
JP2021091704A (ja) * 2019-11-20 2021-06-17 中外製薬株式会社 抗体含有製剤
KR20210064112A (ko) 2019-11-20 2021-06-02 추가이 세이야쿠 가부시키가이샤 항체 함유 제제
WO2021100794A1 (ja) 2019-11-20 2021-05-27 中外製薬株式会社 抗体含有製剤
JP6845973B1 (ja) * 2019-11-20 2021-03-24 中外製薬株式会社 抗体含有製剤
WO2022025030A1 (ja) 2020-07-28 2022-02-03 中外製薬株式会社 新規改変型抗体を含む、針シールドを備えた針付プレフィルドシリンジ製剤
WO2022049614A1 (ja) 2020-09-01 2022-03-10 中外製薬株式会社 Ｉｌ－３１アンタゴニストを有効成分として含有する、透析そう痒症の予防用及び／又は治療用医薬組成物
WO2023058723A1 (ja) 2021-10-08 2023-04-13 中外製薬株式会社 プレフィルドシリンジ製剤の調製方法
WO2023120561A1 (ja) * 2021-12-22 2023-06-29 中外製薬株式会社 生物活性が低下した抗体バリアント

Also Published As

Publication number Publication date
KR101840994B1 (ko) 2018-03-21
CA2708532A1 (en) 2009-06-11
ES2834741T3 (es) 2021-06-18
MX2010006096A (es) 2010-08-04
AU2009323249B2 (en) 2012-04-19
CN101939424B (zh) 2016-12-28
CN101952318B (zh) 2014-07-09
JPWO2009072604A1 (ja) 2011-04-28
KR20170122860A (ko) 2017-11-06
KR20100097721A (ko) 2010-09-03
US9399680B2 (en) 2016-07-26
DK2236604T3 (en) 2016-10-03
AU2008332271B2 (en) 2013-11-07
EP2236604B1 (en) 2016-07-06
CN101952318A (zh) 2011-01-19
AU2008332271A1 (en) 2009-06-11
MX2010007936A (es) 2010-08-16
BRPI0821110A2 (pt) 2015-07-07
US8575317B2 (en) 2013-11-05
EP2236604A1 (en) 2010-10-06
KR101643005B1 (ko) 2016-07-28
RU2010127292A (ru) 2012-01-10
US20150175704A1 (en) 2015-06-25
HUE025958T2 (en) 2016-05-30
CA2710264A1 (en) 2010-06-10
KR20160074019A (ko) 2016-06-27
ES2585480T3 (es) 2016-10-06
EP3095862B1 (en) 2020-09-16
AU2009323249A1 (en) 2010-06-10
EP2236604A4 (en) 2012-08-01
BRPI0821110B1 (pt) 2021-04-20
HRP20151215T1 (hr) 2015-12-04
TW201634479A (zh) 2016-10-01
CA2708532C (en) 2018-06-05
MX337081B (es) 2016-02-10
US20110129459A1 (en) 2011-06-02
JP5682995B2 (ja) 2015-03-11
CN101939424A (zh) 2011-01-05
US20140039165A1 (en) 2014-02-06
US20110229459A1 (en) 2011-09-22
US20230183363A1 (en) 2023-06-15
MY177564A (en) 2020-09-20
CA2710264C (en) 2014-10-07
AU2008332271C1 (en) 2014-04-24
EP3095862A1 (en) 2016-11-23
TW200932266A (en) 2009-08-01
US20200002429A1 (en) 2020-01-02
EP3095862B9 (en) 2021-04-14
TWI548418B (zh) 2016-09-11
BRPI0821110B8 (pt) 2021-05-25
RU2531521C2 (ru) 2014-10-20

Similar Documents

Publication Publication Date Title
WO2009072604A1 (ja) 抗nr10抗体、およびその利用
WO2005074375A3 (en) Heparanase inhibitors and uses thereof
WO2010060937A3 (en) Pharmaceutical combination comprising a hsp 90 inhibitor and a mtor inhibitor
WO2007127263A3 (en) Therapeutic uses of urolithins
BRPI0818366A2 (pt) Composto, pró-droga, medicamento, método inibidor de faah, métodos de profilaxia ou tratamento para ansiedade, ou depressão, ou de alívio da dor, e de profilaxia ou tratamento para dor inflamatória ou dor neuropática, e, uso do composto.
WO2007115305A3 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
WO2007038459A3 (en) Carboxyamine compounds and their use in the treatment of hdac dependent diseases
WO2007038551A3 (en) Use of ibudilast for treating drug and behavioral addictions
WO2007133865A3 (en) Hcv/hiv inhibitors an their uses
WO2007117971A3 (en) Ocular allergy treatments
NL1028599A1 (nl) Verbindingen voor de behandeling van ziekten.
WO2007051785A3 (en) Use of sdf-1 for the treatment and/or prevention of neurological diseases
WO2007121125A3 (en) Hcv inhibitors
WO2002060374A3 (en) Benz-1,3-azole derivatives and their uses as heparanase inhibitors
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
AP2413A (en) 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other disease.
WO2008067982A3 (en) Use of carrageenan for treating rhinovirus infections
WO2007144057A3 (en) Antimicrobial carbon
WO2007106915A8 (en) Antibodies to egfl7 and methods for their use
TNSN08496A1 (en) Aminothiazoles and their uses
MY154715A (en) Anti-nr10 antibody and use thereof
WO2006089664A3 (de) Heterocyclylamid-substituierte imidazole
WO2009103959A3 (en) Histidine and/or histidine derivative for the treatment of inflammatory skin diseases
MX2011009100A (es) Anticuerpo humanizado pcrv que tiene actividad anti-pseudomonal.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880126539.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08857126

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009544736

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 3945/DELNP/2010

Country of ref document: IN

Ref document number: 12010501289

Country of ref document: PH

Ref document number: MX/A/2010/006096

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2708532

Country of ref document: CA

Ref document number: 2008332271

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008332271

Country of ref document: AU

Date of ref document: 20081205

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107014698

Country of ref document: KR

Kind code of ref document: A

REEP Request for entry into the european phase

Ref document number: 2008857126

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2010127292

Country of ref document: RU

Ref document number: 2008857126

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PI 2010002565

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 12745781

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0821110

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100604